Chronic lymphocytic leukemia driven by paradoxical ERK activation during BRAF inhibitor treatment
Whole-exome sequencing of a chronic lymphocytic leukemia (CLL) developed during vemurafenib treatment of a patient with malignant melanoma. Peripheral blood mononuclear cells were separated by Ficoll gradient centrifugation. DNA was extracted from highly purified (>97%) CD19+CD5+ cells obtained from the patient while being under BRAF inhibition versus CD14+ germline control cells (>90% purity). No alterations that could be linked to aberrant RAS activity or paradoxical RAF/MEK/ERK signaling could be identified in the CLL, which shows characteristic copy number alterations.
- 29/03/2016
- 2 samples
- DAC: EGAC00001000452
- Technology: Illumina HiSeq 2500
Data Transfer Agreement for the German Cancer Research Center
To request access to the dataset please start a Data Access Request via the EGA DAC Portal. You will receive a HIPO DACO Info Form by email to collect information about the request, which has to be filled completely and signed by your PI. Your request will be evaluated by the responsible Data Access Committee (DAC) and our Data protection department (and innovation management if required). As soon as a positive decision is made, you will be provided with a data transfer agreement (DTA). After the DTA has been fully signed, access to the requested data is granted. To ensure that the process can be completed as quickly as possible, please note the following points: 1. The request in the EGA portal must be made by the responsible PI. 2. The information in the EGA portal must match the information on the HIPO DACO Info Form. In particular, the email address and the requested data sets must match. It is also important that all requested data sets are also listed on the HIPO DACO Info Form. For-profit companies are charged a fee per request.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| EGAS00001000948 | Other |